Sotagliflozin effective and safe in reducing HbA1c among diabetes patients with CKD
USA: Sotagliflozin 400 but not 200 mg significantly reduced HbA1c compared with placebo after 26 weeks in adults with type 2 diabetes (T2D) and stage 3 chronic kidney disease (CKD3), findings from a phase 3 trial have shown. Sotagliflozin is a dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT1/2).
The researchers also noted a reduction of urine albumin creatinine ratio (UACR) at 26 weeks in patients with at least A2 albuminuria with each of the two doses; the changes did not sustain at week 52. The study appeared in Diabetes, Obesity and Metabolism on 13 February 2023.
Sotagliflozin is a dual sodium–glucose co-transporter-2 and 1 inhibitor for treating both type 2 (T2D) and type 1 (T1D) diabetes. Sotagliflozin inhibits renal sodium-glucose cotransporter 2 and intestinal SGLT-1, delaying glucose absorption and lowering post-prandial glucose.
David Z.I. Cherney from the University of Toronto in Toronto, Canada, and colleagues conducted the phase 3, randomized, placebo-controlled trial to assess the safety and efficacy of sotagliflozin in adults with type 2 diabetes and stage 3 CKD.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.